Metopirone (metyrapone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:		MEMBER'S FIRS	MEMBER'S FIRST NAME:		
important for the review	ut all applicable sections compl (e.g., chart notes or lab data, t alth Information under HIPAA.	o support the authoriza	•	ion contained in	
				URGENT	
MEMBER INFORMATION LAST NAME:	N	FIRST NAME:			
LAST NAIVIE.		FIRST IVAIVIE.			
PHONE NUMBER:		DATE OF BIRTH:	DATE OF BIRTH:		
STREET ADDRESS:					
CITY:		STATE:	ZIP CODE:		
PATIENT INSURANCE ID	NUMBER:				
IF YOU ARE NOT THE PATIENT OR THE FOLLOWING LINK: PRIMETHERAPEUTIC	REPRESENTATIVE (IF APPLICA	DISCLOSURE AUTHORIZATION FOR	M WITH THIS REQUEST WHICH CAN B	SE FOUND AT THE	
	TATIVE'S PHONE NUMBER:				
PRESCRIBER INFORMAT LAST NAME:	ION	FIRST NAME:			
		FIRST IVAIVIL.	FIRST NAIVIE:		
PRESCRIBER SPECIALTY:	:	EMAIL ADDRESS	EMAIL ADDRESS:		
NPI NUMBER:		DEA NUMBER:	DEA NUMBER:		
PHONE NUMBER:		FAX NUMBER:	FAX NUMBER:		
STREET ADDRESS:		·			
CITY:		STATE:	STATE: ZIP CODE:		
REQUESTOR (if different than prescriber):		OFFICE CONTACT	OFFICE CONTACT PERSON:		
MEDICATION OR MEDI	CAL DISPENSING INFORMATION	DN			
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILL	QUANTITY S:	':	
NEW THERAPY DURATION OF THERAPY	RENEWAL (SPECIFIC DATES):	IF RENEWAL: DA	TE THERAPY INITIATED:		

Prime THERAPEUTICS*

Continued on next page

Metopirone (metyrapone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHE	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NO
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	DURATION OF THERAPY (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:
2. LIST DIAGNOSES:		ICD-10:
 □ adrenal insufficiency □ Hyperglycemia secondary to endogenou □ Other diagnosis: 		
3. REQUIRED CLINICAL INFORMATION PRIOR AUTHORIZATION.	N: PLEASE PROVIDE ALL RELEVANT CLINIC	CAL INFORMATION TO SUPPORT A
Is the endogenous Cushing Syndrome secretion of ACTH by nonpituitary turcarcinoma, nodular adrenal hyperpla For renewal of treatment of hypergly Does patient continue to demonstrat	es No se of metopirone prior to ACTH test? No e caused by an ACTH-dependent (e.g., pi mor), or ACTH-independent (e.g., adrend sia)? Yes No Please submit docume remia secondary to endogenous Cushin e a positive clinical response? Yes I	tuitary corticotrope adenoma, ectopic ocortical adenoma, adrenocortical entation. g's Syndrome: No Please submit documentation.
Please note: Not all drugs/diagnosis a information is received.	re covered on all plans. This request may	be denied unless all required
ATTESTATION: I attest the information the Health Plan, insurer, Medical Grounds	on provided is true and accurate to the be up or its designees may perform a routine curacy of the information reported on th	e audit and request the medical
Prescriber Signature or Electronic I.D.	. Verification:	Date:
you are not the intended recipient, you are he	companying this transmission contain confidential reby notified that any disclosure, copying, distribute have received this information in error, please nese documents.	tion, or action taken in reliance on the contents



Metopirone (metyrapone) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: N	MEMBER'S FIRST NAME:
-----------------------	----------------------

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 Phone: 877-228-7909

